Vaccinex, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Vaccinex, Inc. (VCNX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $6.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2025-04-15
- Vaccinex, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $6.00M, a 9.09% decline from fiscal 2023.
- Vaccinex, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $6.60M, a 4.76% increase from fiscal 2022.
- Vaccinex, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $6.30M, a 12.50% decline from fiscal 2021.
- Vaccinex, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $7.20M, a 26.53% decline from fiscal 2020.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2024-12-31 | $6.00M 10-K · filed 2025-04-15 |
| 2023-12-31 | $6.60M 10-K · filed 2025-04-15 |
| 2022-12-31 | $6.30M 10-K/A · filed 2024-04-25 |
| 2021-12-31 | $7.20M 10-K · filed 2023-03-31 |
| 2020-12-31 | $9.80M 10-K · filed 2022-03-31 |
| 2019-12-31 | $11.80M 10-K · filed 2021-03-31 |
| 2018-12-31 | $10.70M 10-K · filed 2020-03-09 |
| 2017-12-31 | -$10.00M 10-K · filed 2019-03-13 |